SCHEMBL1751647

SCHEMBL1751647

N#Cc1nn(-c2c(Cl)cc(OC(F)(F)F)cc2Cl)c(NCC2CC2)c1C1(C(N)=O)CC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 6/20 0.33
PIM1 P11309 7/20 0.33
CHRM4 P08173 1/20 0.33
DRD3 P35462 1/20 0.33
KCNH2 Q12809 2/20 0.32
FLT3 P36888 1/20 0.32
PIM3 Q86V86 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
OPRL1 P41146 1/20 0.32
CYP3A4 P08684 2/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
NR1I2 O75469 1/20 0.32
LMNA P02545 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750830 0.89 GABRP (0.42) KCNH2CYP3A4GABRPGABRDNR1I2
SCHEMBL3555159 0.89 GABRP (0.33) FFAR4PIM1DRD3KCNH2FLT3
SCHEMBL1752112 0.86 GABRP (0.34) FFAR4KCNH2OPRL1CYP3A4GABRP
SCHEMBL12528508 0.86 GABRP (0.31) CYP3A4GABRPGABRDNR1I2LMNA
SCHEMBL2637835 0.85 GABRP (0.34) FFAR4CHRM4DRD3OPRL1CYP3A4
SCHEMBL12528729 0.85 GABRP (0.32) CYP3A4GABRPGABRDNR1I2LMNA
SCHEMBL3556487 0.85 FFAR4 (0.33) FFAR4PIM1CHRM4DRD3KCNH2
SCHEMBL1751399 0.82 GABRP (0.42) FFAR4KCNH2OPRL1CYP3A4GABRP
SCHEMBL1751817 0.81 GABRP (0.41) CYP3A4GABRPGABRDNR1I2LMNA
SCHEMBL3558058 0.81 SLC34A1 (0.33) PIM1KCNH2FLT3PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968584-B2 Substituted arylpyrazoles PFIZER INC. (US) 2011-06-28 US claimed
EP-1893581-B1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES PFIZER LTD (GB) 2010-01-27 EP claimed
US-20090186924-A1 SUBSTITUTED ARYLPYRAZOLES PFIZER INC. (US) 2009-07-23 US claimed
US-7538134-B2 Substituted arylpyrazoles PFIZER INC. (US) 2009-05-26 US claimed
EP-1893581-A1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES Pfizer Limited (GB) 2008-03-05 EP claimed
US-20060287365-A1 Substituted arylpyrazoles ZOETIS LLC 2006-12-21 US claimed
WO-2006134468-A1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES PFIZER LIMITED (GB) 2006-12-21 WO claimed
US-7968584-B2 Substituted arylpyrazoles PFIZER INC. (US) 2011-06-28 US disclosed
US-7968584-B2 Substituted arylpyrazoles PFIZER INC. (US) 2011-06-28 US disclosed
EP-1893581-B1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES PFIZER LTD (GB) 2010-01-27 EP disclosed
EP-1893581-B1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES PFIZER LTD (GB) 2010-01-27 EP disclosed
US-20090186924-A1 SUBSTITUTED ARYLPYRAZOLES PFIZER INC. (US) 2009-07-23 US disclosed
US-20090186924-A1 SUBSTITUTED ARYLPYRAZOLES PFIZER INC. (US) 2009-07-23 US disclosed
US-7538134-B2 Substituted arylpyrazoles PFIZER INC. (US) 2009-05-26 US disclosed
US-20080146643-A1 COMBINATION PFIZER LIMITED (GB) 2008-06-19 US disclosed
WO-2008072077-A2 COMBINATION OF 1-ARYL-4-CYCLOPROPYLPYRAZOLES WITH ANTHELMINTIC AGENT FOR PARASITIC INFESTATION PFIZER LIMITED (GB) 2008-06-19 WO disclosed
EP-1893581-A1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES Pfizer Limited (GB) 2008-03-05 EP disclosed
US-20070149464-A1 COMBINATION PFIZER INC. (US) 2007-06-28 US disclosed
US-20060287365-A1 Substituted arylpyrazoles ZOETIS LLC 2006-12-21 US disclosed
WO-2006134468-A1 SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES PFIZER LIMITED (GB) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146643-A1 COMBINATION PIGO, EPX, PIGS FFAR4 3928/4885PIM1 2933/4885CHRM4 2043/4885
US-20060287365-A1 Substituted arylpyrazoles CYP3A4, CYP3A43, CYP4B1 FFAR4 1302/4885PIM1 290/4885CHRM4 1206/4885
US-20090186924-A1 SUBSTITUTED ARYLPYRAZOLES CYP3A4, CYP3A43, CYP4B1 FFAR4 1302/4885PIM1 290/4885CHRM4 1206/4885
US-20070149464-A1 COMBINATION PIGO, EPX, PIGS FFAR4 3928/4885PIM1 2933/4885CHRM4 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.